Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Bone mineral density in hemodialysis patients with parathyroid dysfunction (1993)
    Springer
    Journal of bone and mineral metabolism 11 (1993), S. S59 
    Details
    ISSN: 1435-5604
    Keywords: Bone mineral density (BMD) ; Single photon absorptiometry (SPA) ; Dual X-ray absorptiometry (DXA) ; Parathyroid function ; Maintenance hemodialysis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We have determined bone mineral density (BMD) in hemodialysis patients with various parathyroid function in an attempt to elucidate the pathology of bone abnormalities, and obtained the following results. It is desirable that BMD (DXA) in the dialysis patients is determined at the radius rather than at the lumber spine. A higher BMD value might be obtained because of osteosclerosis of the vertebra or abdominal vascular calcification. The correlation between the SPA and the DXA was favorable in determining BMD at the distal one-third of the radius. The correlation between Jensen's classification based on subperiosteal resorption, intact-PTH, and BMD(radius) was favorable. The annual decrease in BMD was 4.0% and 4.7% in the male patients within 8 years and the female within 6 years after starting dialysis, respectively, and thier BMD decreased to 70 at above mentioned year. The annual BMD decrease became larger in the patients with severe 2'HPT, i.e., 7.1% in the male patients and 10.0% in the female patients. BMD after PTX markedly increased in the patients showing BMD of less than 70 at PTX. The BMD in one male patient who showed aluminium induced osteomalacia in past history was maintained at a relatively favorable value. The biochemical examination of two female patients who became an aparathyroid state after PTX showed improved values, but their BMD gradually decreased without showing any increase.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02383845
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Efficacy and safety of oral falecalcitriol in reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (1998)
    Springer
    Journal of bone and mineral metabolism 16 (1998), S. 34-43 
    Details
    ISSN: 1435-5604
    Keywords: Key words: falecalcitriol ; ST-630 ; secondary hyperparathyroidism ; parathyroid hormone (PTH) ; double-blind trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract: Based on research conducted so far, active vitamin D3 is known to suppress the secretion of parathyroid hormone (PTH), which is stimulated by chronic renal failure. We investigated the effect and safety of falecalcitriol, a new type of active vitamin D3, in patients with secondary hyperparathyroidism accompanied by chronic renal failure in a multicenter study. In a double-blind study, 121 patients were randomly assigned to a falecalcitriol group (63 patients) or a placebo group (58 patients). They received daily oral falecalcitriol or placebo for 8 weeks. The change rates of intact PTH (i-PTH) , midregion PTH (m-PTH), and carboxy-terminal PTH (c-PTH) were determined as major evaluation parameters. The falecalcitriol group showed a significant suppression (P 〈 .01) of 34.8% in i-PTH; in contrast, the placebo group recorded a significant rise (P 〈 .01) of 12.4%, with a significant difference (P 〈 .01) between the groups. The results for m-PTH and c-PTH were similar to those for i-PTH. Serum calcium, meanwhile, rose significantly (P 〈 .01) in the falecalcitriol group after 2 weeks. The mean values, however, remained within the normal range, and the change rate was within 10%. Apart from the rise in serum calcium, there were no differences in adverse reactions from the placebo group. The results suggest that falecalcitriol is an effective drug against secondary hyperparathyroidism with chronic renal failure because it significantly inhibits a rise in i-PTH under conditions that cause no large changes in serum calcium.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s007740050026
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    A case of polycythemia vera complicated by chronic renal failure under hemodialysis requiring parathyroidectomy for secondary hyperparathyroidisim (1990)
    Springer
    Journal of bone and mineral metabolism 8 (1990), S. 19-23 
    Details
    ISSN: 1435-5604
    Keywords: Polycythemia vera ; Secondary Hyperparathyroidism ; Hemodialysis ; Parathyroid hormone (PTH) ; Uremic toxin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract A case of polycythemia vera complicated by chronic renal failure under maintenance hemodialysis requiring parathyroidectory (PTH) for secondary hyperparathyroidism (2° HPT) is reported. A 62 year old female presented with 75000 white blood cells (WBC)/µl, 703×104 red blood cells (RBC)/µl, 23×104 platelets (PLT)/µl, hyperuricemia and hypertension in 1970 and the diagnosis of polycythemia vera was made. Hemodialysis was started in October 1974 for chronic renal failure. Blood cells in peripheral blood rapidly decreased in number after the beginning of dialysis, reaching the level of 10000∼20000 WBC/µl, and 150∼250×104RBC/µl. In August 1988, marked bone resorption in X-ray picture and high serum alkaline phosphatase and parathyroid hormone (PTH) noted along with 17400 WBC/µl, 370×104RBC/µl and 35.9×104PLT/µl. After subtotal PTX removing 3.21g parathyroid gland, serum PTH rapidly fell. At 3 months after PTX, WBC rose to 23600/µl, RBC 372×104/µl and PLT 94.0×104/µl. At 6 months, WBC was to 31000/µl, RBC 429×104/µl and PLT 78.0×104/µl, suggesting an inhibitory action of PTH on not only RBC, but also WBC and PLT.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02377369
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...